Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Lumen Bioscience is raising $26,052,323.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Brian Finrow played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lumen Bioscience

Lumen Bioscience develops oral antibody therapeutics. Lumen has assembled a team of leading scientists and engineers with deep technical expertise in synthetic biology, protein design, immunology, bioreactor engineering, and cell physiology.  We are headquartered in Seattle, Washington.

To learn more about Lumen Bioscience, visit http://www.lumenbioscience.com/

Contact:
Brian Finrow, Chief Executive Officer
206-899-1904
https://www.linkedin.com/in/finrow/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved